Table 1 Baseline characteristics of the participants according to median of the glucose-to-HbA1c ratio

Male, n (%)

412 (70.3)

209 (71.3)

203 (69.2)

0.59

Age (years)

58.5 ± 13.2

56.9 ± 12.7

60.1 ± 13.5

<0.01

Current smoking, n (%)

207 (35.3)

97 (33.1)

110 (37.5)

0.12

Alcohol consumption, n (%)

252 (43.0)

126 (43.0)

126 (43.0)

0.42

Hypertension, n (%)

560 (95.6)

276 (94.2)

284 (96.9)

0.11

Diabetes mellitus, n (%)

144 (24.6)

58 (19.8)

86 (29.4)

<0.01

Dyslipidemia, n (%)

218 (37.2)

117 (39.9)

101 (34.5)

0.17

History of cerebral infarction, n (%)

96 (16.4)

46 (15.7)

50 (17.1)

0.66

Prior antidiabetic agents, n (%)

75 (12.8)

29 (9.9)

46 (15.7)

0.1

SBP (mmHg)

163.0(150.0–181.0)

160.0 (148.0–177.0)

168.0 (150.0–188.0)

<0.001

DBP (mmHg)

96.0 (83.0–107.0)

95..0 (84.0–105.0)

98.0 (83.0–109.0)

0.21

GCS score

14.0 (12.0–15.0)

15.0 (13.0–15.0)

14.0 (11.0–15.0)

<0.001

NIHSS score

9.0 (3.0–15.0)

7.0 (3.0–13.0)

10.0 (3.0–16.0)

<0.001

Location of hematoma, n (%)

<0.01

 lobar

102 (17.4)

49 (16.7)

53 (18.1)

 deep

363 (62.0)

199 (67.9)

164 (56.0)

 infratentorial

50 (8.5)

20 (6.8)

30 (10.2)

Hematoma volume (ml)

13.0 (5.5–29.4)

10.0 (4.5–21.2)

18.7 (7.4–36.5)

<0.001

intraventricular extension, n (%)

176 (30.0)

59 (20.1)

117 (39.9)

<0.001

eGFR (ml/min)

54.7 (51.1–58.2)

55 .0 (51.6–58.3)

54.3 (50.4–58.0)

0.08

FBG (mmol/l)

5.8 (4.9–7.1)

4.9 (4.4–5.4)

6.8 (6.0–8.2)

<0.001

HbA1c (%)

5.6 (5.3–6.1)

5.6 (5.3–6.1)

5.6 (5.2–6.2)

0.86

hsCRP (mg/l)

8.7 (4.6–8.7)

8.7 (2.8–8.7)

8.7 (8.7–11.1)

<0.001

Post-stroke treatment of hyperglycemia, n (%)

114 (19.5)

41 (14.0)

73 (24.9)

<0.01

Surgery, n (%)

86 (14.7)

14 (4.8)

72 (24.6)

<0.001

Poor functional outcome at discharge, n (%)

292 (49.8)

100 (34.1)

192 (65.5)

<0.001

Poor functional outcome at 90 days, n (%)

256 (43.7)

85 (29.0)

171 (58.4)

<0.001